Mycobacteria are the causative agents of tuberculosis and other serious infectious diseases that are increasingly difficult to treat due to the growing problem of antibiotic resistance. These notorious human pathogens replicate inside macrophages, a crucial cell type of our immune system. In this project a multidisciplinary team of researchers will join forces to elucidate key mechanisms underlying the complex interplay between mycobacterial virulence factors and the macrophage immune defenses. The new insights will be used to explore innovative therapeutic strategies to fight mycobacterial infections.
Company Details
- Founded
- -
- Address
- Leiden-Amsterdam-Nijmegen, Nl
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- HQ
- Leiden-Amsterdam-Nijmegen
- Competitors
- Theme Infection Leiden University Medical Center, The Royal Zoological Society of Scotland, Biochemical Society, Institute of Biology Leiden (IBL), TuBerculosis Vaccine Initiative (TBVI), TBnet, BCRI - Brazilian Clinical Research Institute, Royal Microscopical Society, Alcoholslot Auto, Notarkib NAT Biotech.
Mycobacteriumxl Questions
Mycobacteriumxl's LinkedIn profile is https://nl.linkedin.com/company/mycobacteriumxl
Mycobacteriumxl's industry is
Biotechnology Research
Mycobacteriumxl's top competitors are
Theme Infection Leiden University Medical Center,
The Royal Zoological Society Of Scotland,
Biochemical Society,
Institute Of Biology Leiden (Ibl),
Tuberculosis Vaccine Initiative (Tbvi),
Tbnet,
Bcri - Brazilian Clinical Research Institute,
Royal Microscopical Society,
Alcoholslot Auto,
Notarkib Nat Biotech.
Mycobacteriumxl's categories are Biotechnology Research
Mycobacteriumxl's founding year is 2023
